본문
Participation in Series A rounds by Partners Invest and Medytox Venture Investment
Focus on completing phase 1 clinical trial of selective PARP-1 inhibitor
News 1, Reporter Jin-Joong Hwang, Digmbio, which secured 12 billion won in funding through Series A investment, is starting clinical trials for its next-generation anticancer drug candidate and preclinical testing for a treatment for degenerative brain diseases.
Phase 1 patient recruitment for DM5167 for solid tumor patients is underway.
According to industry sources on the 30th, Digmbio is currently recruiting patients for the phase 1 clinical trial of 'DM5167', a new drug candidate in the second-generation PARP-1 selective inhibitor series.
This study will involve 76 patients with advanced solid tumors. It will evaluate the safety, tolerability, efficacy, and pharmacodynamic characteristics of DM5167. Clinical trials began last year, with patient recruitment beginning in October. The trial is expected to be completed by August 2026.
DM5167 Phase 1 will be conducted at four major medical institutions in Korea, including Seoul National University Hospital, Bundang Seoul National University Hospital, Yonsei University Severance Hospital, and Samsung Seoul Hospital. Patients participating in the clinical trial will receive DM5167 orally on an empty stomach every morning for 28 days as one cycle.
DM5167 is a second-generation targeted anticancer drug candidate that selectively inhibits PARP-1. Digmbio expects DM5167 to effectively overcome hematological toxicity, a major limitation of existing first-generation PARP inhibitors.
In October of last year, Digmbio was selected for the Korea Drug Development Fund (KDDF) Phase 1 clinical trial support program. The company received funding for research and development (R&D) costs related to the DM5167 Phase 1 clinical trial.
Digmbio plans to develop DM5167 as a best-in-class anticancer drug and, after securing proof-of-concept (POC) data in Phase 1 clinical trials, pursue technology transfer to global pharmaceutical companies.
Kim Jeongmin, CEO of Digmbio, said, "If positive results are achieved in Phase 1 clinical trials, we believe technology transfer will be possible," adding, "Completing Phase 1 successfully is one of the important development stages for Digmbio."